Improved crispr-cas technologies
AssigneeSherlock Biosciences, Inc.
InventorsPradeep Ramesh, William Jeremy Blake, Brendan John Manning
Life of this patent
Estimating the term…
Abstract
The present disclosure provides improved CRISPR-Cas proteins (e.g., improved thermostability).
Claims23
A detection method comprising steps of:
- contacting a CRISPR-Cas complex comprising:
- a Cas protein with collateral cleavage activity that is thermostable at temperatures above at least 60-65° C.;
- and
- a guide RNA selected or engineered to be complementary to a target nucleic acid sequence;
- with a sample potentially comprising a target nucleic acid sequence.
9-10. (canceled)
In a method of performing a detection assay utilizing a Cas protein with collateral cleavage activity, the improvement that comprises utilizing a Cas protein with thermostable collateral cleavage activity.
13-15. (canceled)
(canceled)
A non-naturally occurring or engineered composition comprising:
- (a) a Cas protein with collateral cleavage activity that is thermostable at temperatures above at least 60-65° C.;
- and
- (b) at least one guide capable of forming a complex with the Thermostable Cas Protein and directing the complex to bind to a target nucleic acid sequence.
20-21. (canceled)
25-52. (canceled)
A method of cleaving at least one target nucleic acid in a cell comprising contacting a cell with a Cas protein with collateral cleavage activity that is thermostable at temperatures above at least 60-65° C. and at least one guide capable of hybridizing to the at least one target nucleic acid, wherein the Cas protein is capable of forming a complex with the at least one guide and causing a break in the at least one target nucleic acid.
54-80. (canceled)
Dependencies are inferred from the claim text.